de Champs C L, Guelon D P, Garnier R M, Poupart M C, Mansoor O Y, Dissait F L, Sirot J L
Service d'Hygiène Hospitalière, Faculté de Médecine, Clermont-Ferrand, France.
Intensive Care Med. 1993;19(4):191-6. doi: 10.1007/BF01694769.
To study the effect of selective digestive tract decontamination by erythromycin-base on the incidence of carriage and infection with MR Enterobacteriaceae producing an extended spectrum beta-lactamase (ESB).
After a 10-week prospective survey to ascertain the baseline incidence in two bays (1 and 3) of the same ICU, bay 1 was compared with bay 3 during a further survey of 6 months. The patients in bay 1 received erythromycin-base.
Two non-contiguous bays, 1 and 3, of 4 beds, in the same polyvalent ICU of a university hospital.
Consecutive patients with unit stay longer than 2 days; 34 patients were included during the control period, 43 in bay 1 (decontamination) and 46 in bay 3 (control) during the trial period.
Erythromycin-base, 1 g t.i.d. in powder form administered by gastric tube to patients in bay 1 from admission to discharge.
Digestive tract carriage was monitored by cultures of gastric and rectal swab specimens, sampled twice a week. Enterobacteriaceae were isolated on Drigalski agar with incorporated ceftazidime (4 mg/l). In bay 1 there was a decrease in ESB producing Enterobacteriaceae (23% vs 10%, p = 0.0004) from rectal swab, especially in K. pneumoniae (15% vs 2%, p = 10(-5)), during the decontamination period in comparison to the control period. During the trial period the only differences observed between bays 1 and 3 were in the gastric samples: K. pneumoniae were less often isolated in bay 1 than in bay 3 (0% vs 3%, p = 0.03). Intestinal carriage with multiresistant Enterobacteriaceae occurred in 28% patients in bay 1 and 30% patients in bay 3 during the trial period (p = 0.79). Erythromycin-base did not delay the carriage by patients in bay 1 (log rank test p = 0.42).
Erythromycin-base was not effective in preventing digestive tract carriage due to Enterobacteriaceae resistant to third generation cephalosporin by production of chromosomal cephalosporinase. The decrease in isolates containing K. pneumoniae in bay 1 cannot be definitively attributed to erythromycin-base, since the number of this species in bay 3 was low.
研究以红霉素为基础的选择性消化道去污对产超广谱β-内酰胺酶(ESB)的耐甲氧西林肠杆菌科细菌携带率和感染率的影响。
在对同一重症监护病房(ICU)的两个区域(1区和3区)进行为期10周的前瞻性调查以确定基线发病率后,在接下来的6个月调查中对1区和3区进行比较。1区的患者接受以红霉素为基础的治疗。
大学医院同一综合ICU中两个不相邻的4张床位的区域,1区和3区。
连续入住ICU超过2天的患者;对照期纳入34例患者,试验期1区(去污组)43例,3区(对照组)46例。
1区患者从入院至出院期间,通过胃管给予粉末状的红霉素,1g,每日3次。
通过每周两次采集胃和直肠拭子标本进行培养来监测消化道细菌携带情况。在含头孢他啶(4mg/L)的德里加尔斯基琼脂上分离肠杆菌科细菌。与对照期相比,在去污期1区直肠拭子中产ESB的肠杆菌科细菌有所减少(23%对10%,p=0.0004),尤其是肺炎克雷伯菌(15%对2%,p=10⁻⁵)。在试验期,1区和3区之间观察到的唯一差异在于胃标本:1区肺炎克雷伯菌的分离率低于3区(0%对3%,p=0.03)。试验期1区28%的患者和3区30%的患者发生多重耐药肠杆菌科细菌肠道携带(p=0.79)。以红霉素为基础的治疗未延迟1区患者的细菌携带(对数秩检验p=0.42)。
以红霉素为基础的治疗对于预防因产生染色体头孢菌素酶而对第三代头孢菌素耐药的肠杆菌科细菌引起的消化道细菌携带无效。1区肺炎克雷伯菌分离株数量的减少不能明确归因于以红霉素为基础的治疗,因为3区该菌种的数量较少。